Titrating the dose of bromocriptine when treating hyperprolactinemic infertile women

Soto-Albors, Carlos E.; Daly, Douglas C.; Walters, Clifford A.; Ying, Yu Kang; Riddick, Daniel H.

doi:10.1016/s0015-0282(16)48455-4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Bromocriptine1

Treatment Of Prolactinomas1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1986

1995

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A wide range of dosages (1.25-20 mg/day) has been required to normalize PRL levels. 71,72 Oral bromocriptine has the disadvantage of causing nau sea, a significant side effect, which often leads to discontinuation of its use. In this regard, bromocrip tine can be administered vaginally.…”

Section: Bromocriptinementioning

confidence: 99%

Luteal Phase Inadequacy: Diagnosis, Management, and Cost Concerns

Peters¹,

Wentz²

1995

Semin Reprod Med

View full text Add to dashboard Cite

Section: Bromocriptinementioning

confidence: 99%

Luteal Phase Inadequacy: Diagnosis, Management, and Cost Concerns

Peters¹,

Wentz²

1995

Semin Reprod Med

View full text Add to dashboard Cite

“…Patients may respond to doses as small as 1.25mg per day administered in the evening (Fig. 6) and Soto-Albors et al have suggested that patients with hyperprolactinemia may receive titrating doses of bromocryptine until the desired effect is achieved (28). A graded increase in bromocryptine minimizes the common side effects of nausea, vomiting, postural hypotension, dizziness, lethargy, headache, and increases patient compliance.…”

Section: Treatment Of Prolactinomasmentioning

confidence: 99%

Diagnosis and management of prolactinomas

Dollar¹,

Blackwell

1986

Cancer Metast Rev

View full text Add to dashboard Cite

Prolactin secreting tumors account for ten to twenty percent of all intracranial lesions. The patients harboring these tumors present with amenorrhea, galactorrhea, other ovulatory disorders, infertility, delays in puberty and mixed polyendocrinopathy. These tumors are diagnosed by the measurement of serum prolactin levels, Goldmann-Bowl perimetry, and either computed axial tomography or magnetic resonance imaging. Protein secreting tumors are usually benign lesions and historically have been treated by partial or total hypophysectomy or radiation therapy. Surgical resection of the lesion often is followed by recurrence and administration of proton beam radiation therapy results in the development of a panhypopituitary state. Growth of pituitary tumors is controlled with the administration of dopamine agonists such as bromocriptine and prospective studies have suggested that these drugs are now the preferred method of treatment for primary lesions and recurrences.

show abstract

Luteal Function after Ovulation Induction

Fritz¹

1991

Clinical Perspectives in Obstetrics and Gynecology

View full text Add to dashboard Cite

Titrating the dose of bromocriptine when treating hyperprolactinemic infertile women

Cited by 4 publications

References 5 publications

Luteal Phase Inadequacy: Diagnosis, Management, and Cost Concerns

Luteal Phase Inadequacy: Diagnosis, Management, and Cost Concerns

Diagnosis and management of prolactinomas

Luteal Function after Ovulation Induction

Contact Info

Product

Resources

About